HIGHLIGHTS
- who: Agostina Nardone from the Department University of of Pharmacy, Houston, TX, USA have published the paper: The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance, in the Journal: (JOURNAL) of 25/04/2018
- what: The authors have investigated the activity of AZD9496 across a panel of endocrine-sensitive and -resistant breast cancer cell lines and xenograft models and compared the efficacy of AZD9496 with fulvestrant. The authors demonstrate that AZD9496 robustly reduces ER levels and inhibits the growth of both endocrine-resistant and -sensitive . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.